Australia’s trusted immunisation experts
02 November 2022 | NewsAt least two thirds of Australians, including children and adolescents, have had COVID-19, two national antibody studies findRead the full article
Hosted in partnership with the Australasian Society for Infectious Diseases Vaccination Special Interest Group and The University of Sydney.
This webinar, held on 12 February 2021, was the first in the two-part webinar series in preparation for the roll out of COVID-19 vaccines in Australia.
View the video of this webinar to hear from:
William C. (Bill) Gruber
Senior Vice President Vaccine Clinical Research and Development, WRDM, Pfizer Inc.
Bill Gruber is Senior Vice President of Pfizer Vaccine Clinical Research and Development, and responsible for global clinical research and development of vaccines to meet licensure and post licensure requirements. He has over 35 years of experience in vaccine development, including more than 21 years at Pfizer, Inc. and Wyeth. Vaccines investigated or approved include: pneumococcal conjugate, meningococcal conjugate, meningococcal B, influenza, Staph aureus, C. difficile, HIV, RSV, parainfluenza, Group B streptococcus, Lyme, and COVID-19. He is board certified in Pediatrics and Pediatric Infectious Diseases, with authorship of over 200 articles and book chapters.
Professor Katie Flanagan
Australian Technical Advisory Group on Immunisation (ATAGI), Head of Infectious Diseases, Launceston General Hospital
Katie Flanagan is a clinician scientist who has worked on global health issues for more than 25 years. She has led numerous vaccine immunology trials throughout the world. She has been a member of the Australian Technical Advisory Group on Immunisation (ATAGI) since 2019 and currently leads the ATAGI COVID-19 Vaccine Utilisation and Prioritisation Subgroup.